ArticleRSC advances2026
Smartphone-assisted optical quantification of d-penicillamine in human plasm sample using toluidine blue as efficient chromogenic probe: introducing a novel portable device toward therapeutic drug monitoring (TDM).
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
d-Penicillamine (DPA) is a crucial pharmacological agent widely employed in the clinical management of Wilson's disease, rheumatoid arthritis, and heavy metal poisoning due to its potent metal-chelating properties. Given the narrow therapeutic index of DPA and the critical need for precise monitoring to avoid systemic toxicity, developing rapid, sensitive, and accessible analytical methods is highly demanded by clinicians. This study introduces a novel, cost-effective, and sensitive optical sensor for DPA quantification using Toluidine Blue (TB) as the efficient chromogenic probe. Using smartphone-based Digital Image Colorimetry (DIC) coupled with RGB analysis, DPA was measured in the linear concentration range of 0.25 µM to 10 mM in human plasma samples. A key innovation of this research is the implementation of Parafilm-based micro-pad (PF-µPAD) as a portable, hydrophobic sensing substrate for construction of portable optical sensor, which demonstrated exceptional analytical performance for the chemical interaction of analyte-optical probe (DPA-TB), thereby surpassing the accuracy of conventional vial-based colorimetric method. The underlying molecular interaction mechanism was rigorously validated through Zeta potential measurements revealed a substantial shift from +13.4 to -19.3 mV upon DPA interaction with TB, confirming the formation of stable TB-DPA complexes. Furthermore, the assay exhibited suitable selectivity toward DPA against a broad spectrum of amino acids and biological interferents, with dopamine being the only cross-reactive species observed. Finally, the practical utility of this portable sensing platform in human plasma samples, highlighting its strong potential for clinical diagnostics and Therapeutic Drug Monitoring (TDM).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.